Efficacy Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS
-
- STATUS
- Recruiting
-
- participants needed
- 68
-
- sponsor
- Innobioscience SpA
Summary
The purpose of this study is to compare the efficacy and safety of andrographolide 140 mg administered twice a day orally versus a placebo as a modifying treatment of the disease in patients with the progressive forms of Multiple Sclerosis (MS). The principal outcome is to determine the efficacy, of andrographolide in retarding the progression of brain atrophy in patients with progressive forms of MS.
Description
1. Evaluate the clinical efficacy of andrographolide 140 mg administered orally twice a day versus a placebo in: - Delay in the disability capacity progression through the Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Functional Composite (MSFC) at 24 months compared to the baseline. - Delay in cognitive impairment by means of Paced Auditory Serial Addition Test (PASAT), Symbol Digit Modalities Test (SDMT) and depression (Beck) at 24 months compared to the baseline. - Quality of life Multiple Sclerosis Impact Scale (MSIS 29) and fatigue (Krupp) through parameters reported by the patients at at 24 months compared to the baseline. - Tolerability of andrographolide measured by the Treatment Satisfaction Questionnaire for Medication (TSQM) at 24 months. - Delay in the decrease in brain volume measured by Magnetic Resonance (MR) at 24 months compared to the baseline. - Number and volume of new lesions or larger size in T2 by MR at 24 months compared to the baseline. - Number of new hipointense lesions in T1 or (gadolinium captive) by MR at 24 months compared to the baseline. - Delay in the retineal thinning measured by Optical Coherence Tomography (OCT) and visual field at 24 months compared to the baseline. - Safety of andrographolide at 24 months through the record of adverse effects in symptom dairy and programmed interviews. 2. Explore the pharmacokinetic of andrographolide 140 mg administered orally twice day in: - bio availability and concentration of andrographolide in the patients with treatment. - half-life, maximum concentration, clearance of andrographolide in equilibrium state. 3. Determine the immunomodulatory effects of andrographolide 140 mg administered twice a day orally on lymphocyte populations in patients through the: - Determination of Th1, Th2, Th17 and Treg lymphocyte sub-populations. - Determination of cytokines IFNgama, TNFalpha, IL2, IL17alpha and TGFbeta. Population: adult patients, men and women with progressive forms of MS. The number of patients to be selected will be 68, to randomly assign 34 patients to each group.
Details
| Condition | Chronic progressive multiple sclerosis |
|---|---|
| Treatment | Placebo, Andrographolides |
| Clinical Study Identifier | NCT02273635 |
| Sponsor | Innobioscience SpA |
| Last Modified on | 7 November 2020 |
Eligibility
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer